Skip to main content

Neurome Announces Partnership With ImClone Systems

NEW YORK, Sept. 24, (GenomeWeb News) - Neurome announced today that it has entered into a research agreement with ImClone Systems in which Neurome will apply its proprietary technologies and expertise in quantitative neuropathology to assist ImClone Systems in the discovery of preclinical candidate molecules.

           

Financial terms of the agreement were not disclosed.

 

"We believe ImClone Systems' decision to work with Neurome is an important validation of our discovery stage capabilities and proprietary technologies," said Floyd Bloom, chairman and founding CEO of Neurome.

 

In August, Neurome announced that it plans to buy all the assets owned by Digital Gene Technologies, including its gene-expression assays and gene-expression-analysis platform called TOGA (see story on Aug. 11).

 

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.